TG Therapeutics (NASDAQ:TGTX – Get Free Report) and Pyxis Oncology (NASDAQ:PYXS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.
Institutional and Insider Ownership
58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Comparatively, 10.5% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and price targets for TG Therapeutics and Pyxis Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TG Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
| Pyxis Oncology | 1 | 0 | 7 | 0 | 2.75 |
Valuation & Earnings
This table compares TG Therapeutics and Pyxis Oncology”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TG Therapeutics | $616.29 million | 15.72 | $447.18 million | $0.66 | 97.14 |
| Pyxis Oncology | $13.86 million | 9.24 | -$79.62 million | ($1.30) | -1.18 |
TG Therapeutics has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
TG Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.
Profitability
This table compares TG Therapeutics and Pyxis Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TG Therapeutics | 11.81% | 18.82% | 7.78% |
| Pyxis Oncology | N/A | -252.36% | -120.63% |
Summary
TG Therapeutics beats Pyxis Oncology on 12 of the 15 factors compared between the two stocks.
About TG Therapeutics
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.
About Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue. The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
